文献速递流行病学与生物统计临床试验与 GCP

利用替代终点预测未来临床试验成功概率的方法学

Predictive probability of success using surrogate endpoints.
PubMed 文献 · Stat Med · 2018-12-12

该研究提出一种基于替代终点的预测未来临床试验成功概率的通用方法。方法利用历史试验中一个或多个替代终点的结果构建替代先验,并在贝叶斯框架下与临床终点数据结合,同时提出两种处理替代先验与临床终点数据潜在不一致的方法。模拟研究考察了预测行为模式,并以多发性硬化药物开发为例展示应用。

要点

  • 替代先验整合历史替代终点证据,可弥补临床终点数据不足。
  • 贝叶斯框架下替代先验可与历史临床终点数据结合使用。
  • 提出两种方法处理替代先验与临床终点数据间的不一致。

核心结论

  • 所提方法可从替代终点预测未来试验成功概率,并充分利用所有可用证据。
  • 该方法有望支持药物开发中的决策,加速开发并更早筛选有前景的候选药物。

研究设计与样本

  • 方法学研究:提出基于替代先验的预测方法,并进行综合模拟研究。
  • 以多发性硬化药物开发为应用实例展示方法。

主要发现

  • 综合模拟研究考察了预测在多种情形下的行为模式。
  • 在多发性硬化药物开发中的应用展示了方法的可行性。

临床怎么用

  • 在早期开发以替代终点为主要终点、临床终点数据有限时,可用该方法预测未来试验成功概率。
  • 贝叶斯框架下可将替代先验与历史临床终点数据结合,辅助药物开发决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The predictive probability of success of a future clinical trial is a key quantitative tool for decision-making in drug development. It is derived from prior knowledge and available evidence, and the latter typically comes from the accumulated data on the clinical endpoint of interest in previous clinical trials. However, a surrogate endpoint could be used as primary endpoint in early development and, usually, no or limited data are collected on the clinical endpoint of interest. We propose a general, reliable, and broadly applicable methodology to predict the success of a future trial from surrogate endpoints, in a way that makes the best use of all the available evidence. The predictions are based on an informative prior, called surrogate prior, derived from the results of past trials on one or several surrogate endpoints. If available, in a Bayesian framework, this prior could be combined with data from past trials on the clinical endpoint of interest. Two methods are proposed to address a potential discordance between the surrogate prior and the data on the clinical endpoint. We investigate the patterns of behavior of the predictions in a comprehensive simulation study, and we present an application to the development of a drug in Multiple Sclerosis. The proposed methodology is expected to support decision-making in many different situations, since the use of predictive markers is important to accelerate drug developments and to select promising drug candidates, better and earlier.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Saint-Hilary G, Barboux V, Pannaux M, et al. Predictive probability of success using surrogate endpoints. Stat Med. 2018. PMID: 30548627. doi:10.1002/sim.8060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。